 | • レポートコード：QYR2104Z0871 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、膀胱がん治療・診断のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、免疫療法、放射線療法、その他）、用途別市場規模（病院、腫瘍治療センター、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・膀胱がん治療・診断の市場動向 ・企業の競争状況、市場シェア ・膀胱がん治療・診断の種類別市場規模（化学療法、免疫療法、放射線療法、その他） ・膀胱がん治療・診断の用途別市場規模（病院、腫瘍治療センター、外来手術センター、その他） ・膀胱がん治療・診断の北米市場規模2016-2027（アメリカ、カナダ） ・膀胱がん治療・診断のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・膀胱がん治療・診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・膀胱がん治療・診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・膀胱がん治療・診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、GlaxoSmithKline、Merck、Novartis、Bristol-Myers Squibb、Eli Lilly、Roche、Sanofi、AstraZeneca、Celgene Corporation） ・結論 |
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
Market Analysis and Insights: Global Bladder Cancer Therapeutics and Diagnostics Market
The global Bladder Cancer Therapeutics and Diagnostics market size is projected to reach US$ 664.8 million by 2026, from US$ 415.6 million in 2019, at a CAGR of 6.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bladder Cancer Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bladder Cancer Therapeutics and Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bladder Cancer Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bladder Cancer Therapeutics and Diagnostics market.
Global Bladder Cancer Therapeutics and Diagnostics Scope and Market Size
Bladder Cancer Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bladder Cancer Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy
Immunotherapy
Radiation Therapy
Others
Segment by Application
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
GlaxoSmithKline
Merck
Novartis
Bristol-Myers Squibb
Eli Lilly
Roche
Sanofi
AstraZeneca
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Radiation Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Bladder Cancer Therapeutics and Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Oncology Treatment Centers
1.3.4 Ambulatory Surgery Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Bladder Cancer Therapeutics and Diagnostics Market Perspective (2016-2027)
2.2 Bladder Cancer Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Bladder Cancer Therapeutics and Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bladder Cancer Therapeutics and Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Bladder Cancer Therapeutics and Diagnostics Industry Dynamic
2.3.1 Bladder Cancer Therapeutics and Diagnostics Market Trends
2.3.2 Bladder Cancer Therapeutics and Diagnostics Market Drivers
2.3.3 Bladder Cancer Therapeutics and Diagnostics Market Challenges
2.3.4 Bladder Cancer Therapeutics and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bladder Cancer Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Bladder Cancer Therapeutics and Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Bladder Cancer Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bladder Cancer Therapeutics and Diagnostics Revenue
3.4 Global Bladder Cancer Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bladder Cancer Therapeutics and Diagnostics Revenue in 2020
3.5 Bladder Cancer Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Bladder Cancer Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Bladder Cancer Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bladder Cancer Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027)
5 Bladder Cancer Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size (2016-2027)
6.2 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type
6.2.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2027)
6.3 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application
6.3.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2027)
6.4 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country
6.4.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size (2016-2027)
7.2 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type
7.2.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2027)
7.3 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application
7.3.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2027)
7.4 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country
7.4.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type
8.2.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application
8.3.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region
8.4.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size (2016-2027)
9.2 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type
9.2.1 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application
9.3.1 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country
9.4.1 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type
10.2.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application
10.3.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country
10.4.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Bladder Cancer Therapeutics and Diagnostics Introduction
11.1.4 Pfizer Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Introduction
11.2.4 GlaxoSmithKline Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.2.5 GlaxoSmithKline Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Bladder Cancer Therapeutics and Diagnostics Introduction
11.3.4 Merck Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Bladder Cancer Therapeutics and Diagnostics Introduction
11.4.4 Novartis Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Bladder Cancer Therapeutics and Diagnostics Introduction
11.6.4 Eli Lilly Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.6.5 Eli Lilly Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Bladder Cancer Therapeutics and Diagnostics Introduction
11.7.4 Roche Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.7.5 Roche Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Bladder Cancer Therapeutics and Diagnostics Introduction
11.8.4 Sanofi Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Bladder Cancer Therapeutics and Diagnostics Introduction
11.9.4 AstraZeneca Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.9.5 AstraZeneca Recent Development
11.10 Celgene Corporation
11.10.1 Celgene Corporation Company Details
11.10.2 Celgene Corporation Business Overview
11.10.3 Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Introduction
11.10.4 Celgene Corporation Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
11.10.5 Celgene Corporation Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Immunotherapy
Table 4. Key Players of Radiation Therapy
Table 5. Key Players of Others
Table 6. Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2016-2021)
Table 10. Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Table 12. Bladder Cancer Therapeutics and Diagnostics Market Trends
Table 13. Bladder Cancer Therapeutics and Diagnostics Market Drivers
Table 14. Bladder Cancer Therapeutics and Diagnostics Market Challenges
Table 15. Bladder Cancer Therapeutics and Diagnostics Market Restraints
Table 16. Global Bladder Cancer Therapeutics and Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Players (2016-2021)
Table 18. Global Top Bladder Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bladder Cancer Therapeutics and Diagnostics as of 2020)
Table 19. Ranking of Global Top Bladder Cancer Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Bladder Cancer Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Bladder Cancer Therapeutics and Diagnostics Product Solution and Service
Table 23. Date of Enter into Bladder Cancer Therapeutics and Diagnostics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Table 27. Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Bladder Cancer Therapeutics and Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
Table 31. Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Company Details
Table 64. Pfizer Business Overview
Table 65. Pfizer Bladder Cancer Therapeutics and Diagnostics Product
Table 66. Pfizer Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. GlaxoSmithKline Company Details
Table 69. GlaxoSmithKline Business Overview
Table 70. GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Product
Table 71. GlaxoSmithKline Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 72. GlaxoSmithKline Recent Development
Table 73. Merck Company Details
Table 74. Merck Business Overview
Table 75. Merck Bladder Cancer Therapeutics and Diagnostics Product
Table 76. Merck Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 77. Merck Recent Development
Table 78. Novartis Company Details
Table 79. Novartis Business Overview
Table 80. Novartis Bladder Cancer Therapeutics and Diagnostics Product
Table 81. Novartis Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 82. Novartis Recent Development
Table 83. Bristol-Myers Squibb Company Details
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Product
Table 86. Bristol-Myers Squibb Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Eli Lilly Company Details
Table 89. Eli Lilly Business Overview
Table 90. Eli Lilly Bladder Cancer Therapeutics and Diagnostics Product
Table 91. Eli Lilly Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 92. Eli Lilly Recent Development
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Bladder Cancer Therapeutics and Diagnostics Product
Table 96. Roche Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 97. Roche Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 101. Sanofi Recent Development
Table 102. AstraZeneca Company Details
Table 103. AstraZeneca Business Overview
Table 104. AstraZeneca Bladder Cancer Therapeutics and Diagnostics Product
Table 105. AstraZeneca Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 106. AstraZeneca Recent Development
Table 107. Celgene Corporation Company Details
Table 108. Celgene Corporation Business Overview
Table 109. Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Product
Table 110. Celgene Corporation Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 111. Celgene Corporation Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Immunotherapy Features
Figure 4. Radiation Therapy Features
Figure 5. Others Features
Figure 6. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Oncology Treatment Centers Case Studies
Figure 9. Ambulatory Surgery Centers Case Studies
Figure 10. Others Case Studies
Figure 11. Bladder Cancer Therapeutics and Diagnostics Report Years Considered
Figure 12. Global Bladder Cancer Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Bladder Cancer Therapeutics and Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2027
Figure 15. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Figure 16. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Players in 2020
Figure 17. Global Top Bladder Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bladder Cancer Therapeutics and Diagnostics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Bladder Cancer Therapeutics and Diagnostics Revenue in 2020
Figure 19. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Figure 20. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027)
Figure 21. North America Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 23. North America Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 24. North America Bladder Cancer Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 25. United States Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 29. Europe Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 30. Europe Bladder Cancer Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 31. Germany Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Share by Region (2016-2027)
Figure 41. China Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 49. Latin America Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 50. Latin America Bladder Cancer Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 51. Mexico Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 57. Turkey Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 61. GlaxoSmithKline Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 65. Eli Lilly Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 66. Roche Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 67. Sanofi Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 68. AstraZeneca Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 69. Celgene Corporation Revenue Growth Rate in Bladder Cancer Therapeutics and Diagnostics Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
世界の膀胱がん治療市場規模・現状・予測（2021年-2027年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…- 世界の腎臓がん治療・診断市場規模・現状・予測（2021年-2027年） The occurrence of kidney cancer has increased in the recent years. Excessive smoking, rise in obesity because of sedentary life routines and increased consumption of alcohol are some of the causes of kidney cancer. The most common type of cancer is Renal Cell Carcinoma (RCC).Immunotherapies or targe…
- 世界の卵巣がん診断＆治療市場規模・現状・予測（2021年-2027年） Ovarian cancer is often fatal because it is usually advanced when diagnosed. Symptoms are usually absent in early stages and nonspecific in advanced stages.The goal of treatment for ovarian cancer is to surgically remove as much of the cancer as possible through the debulking and then to provide wha…
- 世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). North America is the largest consumption market of Overactive …
- 世界の皮膚がん診断＆治療市場規模・現状・予測（2021年-2027年） On the basis of the type of tissue affected, there are three major types of skin cancer, namely, basal cell carcinoma, squamous-cell carcinoma, and melanoma. Factors such as increasing incidences of skin cancer, favorable government initiatives, the development of novel immunotherapies, and the exte…